Professor Yong-Jie Lu

Professor Yong-Jie Lu

MBBS, MD, PhD
Centre: Molecular Oncology
Professor of Molecular Oncology
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory


We aim to identify genomic alterations and genetic risk factors that influence the development, progression and therapeutic responses of male urogenital tumours, in particular prostate cancer.

Research Details

I have set up a research programme of systematic genetic studies of prostate cancer, renal cancer and testicular germ cell tumours (TGCT). The mission of the research team is to identify, using a systematic approach, genomic alterations and genes significance in influencing the development, progression and therapeutic response of male urogenital tumours.

Recently, I have also started an investigation of genetic and environmental factors associated with key genomic alterations in prostate cancer. While the identification of genetic alterations will help us to understand the molecular mechanisms of cancer development and to develop useful biomarkers for tumour behaviour and potential targets for novel therapies, the identification of factors associated with specific genomic alterations will lead to improved cancer prevention. There are currently five main research areas of interest:

  • Identification of critical genes in the development and progression of prostate cancer using the genome-wide analysis approach.
  • Investigation of the mechanism and consequence of genomic alterations, particularly rearrangements/translocations, in prostate cancer development.
  • Investigation of the genetic and environmental factors associated with key genomic alterations in prostate cancer.
  • Experimental therapy based on specific genetic changes in cancer cells.
  • The resistance mechanism of targeted therapies of renal cancer.

Profile

Education

  • 1992-1995: Ph.D. student in Chinese Academy of Medical Sciences (CAMS) &  Peking Union Medical College (PUMC), Beijing. (Pathophysiology)
  • 1989-1992    Post-graduate student in Dept. of Biology, Harbin Medical University. (M.D. Medical Genetics.)
  • 1984-1989    Undergraduate medical student in Faculty of Medicine, Henan Medical University.

Appointments

  • July 2010- present: Reader (Team Leader), Barts Cancer Institute, Barts and London School of Medicine and Dentistry, Queen Mary University of London (QMUL), London.
  • Jun. 2003-July 2010: Senior Lecturer (Team Leader), Barts Cancer Institute, Barts and London School of Medicine and Dentistry, QMUL.
  • Oct. 2001-Jun. 2003: Research Associate (deputy Team Leader), Molecular Cytogenetics Laboratory, The Institute of Cancer Research (ICR), Sutton, UK.
  • Apr. 2000-Oct. 2001: Senior postdoctoral scientist, Molecular Cytogenetics Laboratory, Section of Paediatrics (joint with Section of Molecular Carcinogenesis), ICR, Sutton, UK.
  • Apr. 1997-Apr. 2000: Postdoctoral scientist, Molecular Cytogenetics Laboratory, Section of Cell Biology & Experimental Pathology, ICR, Sutton, UK.
  • Oct. 1995-Jan. 1997: Visiting Scholar, Molecular Cytogenetics Laboratory, ICR, Sutton, UK.

Funding

2015 Angle Europe PLC "Evaluation of a size-based circulating tumour cell isolation system, Parsortix, for its application in prostate cancer"
£78,300
2015

The Orchid Cancer Appeal

"Investigating the potential of Brentuximab Vedotin for testicular germ cell tumour treatment"
£60,000
2015 The Orchid Cancer Appeal "Prostate cancer prognostic biomarker and circulating biomarker studies"
£172,000

2014

The Orchid Cancer Appeal * "Systematic studies of genetic alterations and identification of genes involved in male urological tumour development and progression"
£174,000
2013 The Orchid Cancer Appeal (As above*)
£172,000

2012

The Orchid Cancer Appeal (As above*)
£172,000

2011

Prostate Action

Confirmation of TCBA1 (NKAIN2) as a candidate tumour suppressor gene at 6q region in prostate cancer
£59,140
2011-2014 Queen Mary College Funds PhD Studentship: "Novel approach for prostate cancer therapy using TMPRSS2 promoter activity"
£62,000

2010

The Orchid Cancer Appeal

(As above*)
£171,680

2010

(As above*)
£164,080
2010-2013 Medical Research Council Industrial Case PhD Studentship (Joint application with Tom Powles): "The role of Src and its inhibition in urological cancers"
£75,000

2009

The Orchid Cancer Appeal

Yearly Award 2009/10
£157,210

2009

Association for International Cancer Research

The role of ZDHHC14
£192,685

2008

Medical Research Council

Associated genes in prostate cancer
£303,225

2008

The Orchid Cancer Appeal

CA Genetics Project 08/09
£182,420

Key Publications

Marzec J, Mao X, Li M, Wang M, Feng N, Gou X, Wang G, Sun Z, Xu J, Xu H, Zhang X, Zhao SC, Ren G, Yu Y, Wu Y, Wu J, Xue Y, Zhou B, Zhang Y, Xu X, Li J, He W, Benlloch S, Ross-Adams H, Chen L, Li J, Hong Y, Kote-Jarai Z, Cui X, Hou J, Guo J, Xu L, Yin C, Zhou Y, Neal DE, Oliver T, Cao G, Zhang Z, Easton DF, Chelala C; PRACTICAL Consortium; CHIPGECS Group, Al Olama AA, Eeles RA, Zhang H, Lu YJ. A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. Oncotarget. (2016) Feb 8. doi: 10.18632. Oncotarget.7250. PMID: 26881390

Coll Bastus N, Mao X, Young BD, Sheer D, Lu YJ. DNA replication-dependent induction of gene proximity by androgen. Hum Mol Genet. (2015) 15;24(4):963-71. PMID: 25281662

Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Lin D, Marzec J, Vasiljević N, Chaplin T, Xue L, Xu M, Foster JM, Karnam SS, James SY, Chioni AM, Gould D, Lorincz AT, Oliver RT, Chelala C, Thomas GM, Shipley JM, Mather SJ, Berney DM, Young BD, Lu YJ. Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol. (2014) 232(5):566-77. PMID: 24407904

Mao X, Yu Y, Boyd LK, Ren G, Stankiewicz E, Lin D, Chaplin T, Kudahetti SC, Xue L, Beltran L, Gupta M, Oliver RTD, Lemoine NR, Berney DM, Young BD, Lu YJDistinct genomic alterations suggest alternative pathways of prostate carcinogenesis in Chinese and Western populations. Cancer Res (2010) 70(13):5207-12. PMID: 20516122


Further Publications

For additional publications, please click here.


We aim to identify genomic alterations and genetic risk factors that influence the development, progression and therapeutic responses of male urogenital tumours, in particular prostate cancer.

External Activities

  • Senior Editor: American Journal of Cancer Research
  • Editorial Board Member: The Open Breast Cancer Journal.
  • Editorial Board Member: Journal of Cancer Research Updates.
  • Scientific assessment committee member: France national cancer research programme Canceropole (2007-2014).
  • Research grant reviewer for funding bodies, such as British Medical Research Council (MRC), British National Institute for Health Research (NIHR), UK Prostate Action, Prostate Cancer Research Charity, National Cancer Institute of France, International Association of Cancer Research, Hong Kong Research Grants Council.
  • Referee of scientific journals such as Oncogene, J Path, Gene Chromosome Cancer, Br J Cancer, International J Cancer, Carcinogenesis, PloS One, BMC Cancer and Histopathology. Active Member of American Association for Cancer Research.
  • Honorable Professor, Second Military Medical University, Shanghai, China
  • Honorable Professor, Chongqing Medical University, Chongqing, China
  • Honorable Professor, Department of Pathology, Zhengzhou University Medical College, China.

News

  • November 2016 - our latest work on detecting circulating prostate tumour cells is covered in the media, and we received at poster prize at the NCRI conference.

See other researchers working on:

Cancer and Ageing Genetics Genitourinary Cancer Prostate
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.